 CAMBRIDGE, Mass., April 02, 2020 GLOBE NEWSWIRE -- Fulcrum Therapeutics, Inc. FULC, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business update in the context of the developing situation with the COVID-19 coronavirus pandemic. During the unprecedented challenges we all face with the SARS-CoV-2 pandemic, we have recently implemented plans to protect the safety, health and well-being of the patients, families and healthcare professionals involved in our clinical development programs, as well as our employees, said Robert J. Gould, Ph.D., Fulcrums president and chief executive officer. While we are fully focused on moving our clinical programs forward, Fulcrum supports this temporary reallocation of resources to ensure hospitals and healthcare workers can focus on meeting the needs of patients with COVID-19. 